Ipilimumab/Nivolumab for Favorable-Risk mRCC

Ipilimumab/Nivolumab for Favorable-Risk mRCC

A debate on the use of ipilimumab/nivolumab as treatment for patients with favorable-risk metastatic renal cell carcinoma. Website: https://www.onclive.com Twitter:   / onclive   Facebook:   / onclive   LinkedIn:   / onclive